Rani Therapeutics Holdings (RANI) EBIT (2020 - 2026)
Rani Therapeutics Holdings' (RANI) quarterly EBIT came in at -$8.3 million in Q1 2026, up 30.58% year-on-year from -$6.4 million in Q1 2025, and up 2.3% quarter-over-quarter from -$8.5 million in Q4 2025.
Rani Therapeutics Holdings (RANI) EBIT (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' EBIT history runs 7 years deep, the most recent figure standing at -$8.3 million for Q1 2026.
- On a quarterly basis, EBIT rose 30.58% year-over-year to -$8.3 million in Q1 2026; TTM through Mar 2026 was -$34.6 million, a 32.48% increase from a year earlier, with the FY2025 full-year figure at -$38.3 million, up 28.14% from the prior year.
- EBIT grew to -$8.3 million in Q1 2026 per RANI's latest filing, from -$8.5 million in the prior quarter.
- Across five years, EBIT topped out at -$7.3 million in Q3 2025 and bottomed at -$18.3 million in Q2 2023.
- The 5-year median for EBIT is -$13.8 million (2022), against an average of -$13.5 million.
- Across the five-year window, EBIT sank 201.39% in 2022 and surged 42.94% in 2025, its largest moves.
- Year by year, EBIT stood at -$17.5 million in 2022, then gained by 23.16% to -$13.4 million in 2023, then slipped by 11.34% to -$15.0 million in 2024, then surged by 42.94% to -$8.5 million in 2025, then rose by 2.3% to -$8.3 million in 2026.
- Per Business Quant, the three latest RANI EBIT figures stand at -$8.3 million (Q1 2026), -$8.5 million (Q4 2025), and -$7.3 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Rani Therapeutics Holdings | 160.20 Mn | 167.33 Mn | - | -8.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.34 Mn |
| Dec 31, 2025 | -8.54 Mn |
| Sep 30, 2025 | -7.26 Mn |
| Jun 30, 2025 | -10.51 Mn |
| Mar 31, 2025 | -12.01 Mn |
| Dec 31, 2024 | -14.96 Mn |
| Sep 30, 2024 | -11.80 Mn |
| Jun 30, 2024 | -12.52 Mn |
| Mar 31, 2024 | -14.03 Mn |
| Dec 31, 2023 | -13.43 Mn |
| Sep 30, 2023 | -17.86 Mn |
| Jun 30, 2023 | -18.29 Mn |
| Mar 31, 2023 | -16.52 Mn |
| Dec 31, 2022 | -17.48 Mn |
| Sep 30, 2022 | -16.34 Mn |
| Jun 30, 2022 | -15.85 Mn |
| Mar 31, 2022 | -13.78 Mn |
| Dec 31, 2021 | -13.36 Mn |
| Sep 30, 2021 | -27.78 Mn |
| Jun 30, 2021 | -5.26 Mn |